Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Mimedx Group (MDXG) Research & Development: 2011-2024

Historic Research & Development for Mimedx Group (MDXG) over the last 14 years, with Dec 2024 value amounting to $12.3 million.

  • Mimedx Group's Research & Development rose 26.90% to $3.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $13.9 million, marking a year-over-year increase of 24.11%. This contributed to the annual value of $12.3 million for FY2024, which is 2.56% down from last year.
  • According to the latest figures from FY2024, Mimedx Group's Research & Development is $12.3 million, which was down 2.56% from $12.7 million recorded in FY2023.
  • Over the past 5 years, Mimedx Group's Research & Development peaked at $12.7 million during FY2022, and registered a low of $9.9 million during FY2021.
  • Its 3-year average for Research & Development is $12.6 million, with a median of $12.7 million in 2023.
  • In the last 5 years, Mimedx Group's Research & Development declined by 15.22% in 2021 and then climbed by 27.88% in 2022.
  • Over the past 5 years, Mimedx Group's Research & Development (Yearly) stood at $11.7 million in 2020, then dropped by 15.22% to $9.9 million in 2021, then grew by 27.88% to $12.7 million in 2022, then dropped by 0.28% to $12.7 million in 2023, then dropped by 2.56% to $12.3 million in 2024.